Feasibility of breast conservation after neoadjuvant taxene based chemotherapy in locally advanced breast cancer: a Prospective Phase I trial

Elsayed, Mohamed; Maximous, Doaa; Aboziada, Mohamed A; Abdel-Wanis, Mostafa E.; Mikhail, Nabiel

doi:10.1186/1750-1164-4-5

Cited by 7 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several other studies have shown a similar overall objective response of the primary tumor in patients with locally advanced breast cancer ranging from 71 to 87 %. 7,8,9 On the other hand, the present results are much higher than that reported by Yadav et al who found that only 23 % showed response to neoadjuvant chemotherapy. 10 Another study by Tamer et al in 2010 also showed much lesser overall response rates to neoadjuvant chemotherapy 54.5 %(CR 3% and PR 51.5%) and Kim et al also reported that the overall response rate to neoadjuvant chemotherapy is 60 %(CR 4 % and PR 56%) respectively.…”

Section: Discussioncontrasting

confidence: 56%

A study on role of neo adjuvant chemotherapy in locally advanced non-metastatic breast cancer

Siddhartha

Kanchana

2018

Int Surg J

View full text Add to dashboard Cite

Background: Nearly 1.7 million new breast cancer cases were diagnosed worldwide in 2012.Breast cancer is the second most common cancer in women worldwide. Globally, breast cancer now represents one in four of all cancers in women. breast cancer has ranked number one cancer among Indian females with age adjusted rate as high as 25.8 per 100,00 women and mortality 12.7 per 100,000 women. Around 90,000 new cases of breast cancer are diagnosed every year in India and majority present as Locally Advanced Breast Cancer (LABC). Neo adjuvant chemotherapy is a commonly used modality for LABC, that gives an upfront systemic therapy in high risk patients with expected micro metastatic burden and also helps in down staging the disease and offering radical cure.Methods: All Locally Advanced Non-Metastatic Breast Carcinoma (T3 N0, T3 N1, T4a, T4b, T4c, Any N2/N3, MO patients who received Neo Adjuvant Chemotherapy and underwent surgery were included. All these patients received 5-Fluorouracil, Adriamycin and Cyclophosphamide (FAC) regime, following therapy patients were offered either Modified Radical Mastectomy or Breast Conservative Surgery with axillary node dissection and Radiotherapy.Results: Complete response was achieved in 20 (66.6%) patients,3 (10%) of the patients had partial response and 7 (23.3%) progressed clinically.Conclusions: Neo adjuvant chemotherapy helped to study response of tumour size to NAC, down stage disease and to convert inoperable cases to resectability.

show abstract

Section: Discussioncontrasting

confidence: 56%

A study on role of neo adjuvant chemotherapy in locally advanced non-metastatic breast cancer

Siddhartha

Kanchana

2018

Int Surg J

View full text Add to dashboard Cite

show abstract

“…The overall response to NACT in this study was 90% (Partial = 77% and complete = 13%). Several other studies proclaimed that NACT response to LABC is ranging from 71% to 87% [20]. Interestingly, our results were the highest from this point of view.…”

Section: Discussionsupporting

confidence: 50%

Assessment of Clinico Pathological Factors as Predictive Markers in Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (LABC)

Akter,

Hossoin,

Alam

et al. 2024

Arch Oncol Cancer Ther

View full text Add to dashboard Cite

Background: A good plan of management is extremely important for the personalized management of breast cancer. In locally advanced breast cancer, neoadjuvant chemotherapy has a vital role in good subsequent management. There are some predictors for the assessment of clinical and pathological response. Aim of the Study:To observe the clinical and pathological factors as predictors for responsiveness of NACT in LABC patients.Methods: It was a cross-sectional comparative study that was conducted among the patients of the Department of Surgical Oncology of NICRH from October 2016 to September 2017. Initially, all the patients were enrolled by purposive sampling. After that, they were scrutinized by eligibility criteria. One hundred patients were selected. A pre-formed, structured, peer-reviewed data collection sheet was prepared, which was used to collect data. Data were compiled, edited, managed and analyzed. The results were tabulated in table and figure form. Data analysis was done by chi-square test. The p-value was significant at <0.05.Result: Out of the total, 42% and 28% belonged to the 41-50 years and 31-40 years age group respectively. The mean age was 44.51±10.77 years, and the age range was 22-73 years. Among 100 patients, 76% had a BMI between 18.5 and 24.99. Subsequently, 13% of patients had it between 25 and 29.99. The mean BMI of the respondents was 23.81±2.36. The BMI range was 17.83-31.13. 86% of patients were homemakers, 95% were married, and 92% had a history of breastfeeding. Out of 100 patients, 6% had a positive family history of breast cancer. Among 100 patients, 69% never took any form of hormonal contraceptive in their lifetime. Out of 100 patients, 87% patients were pre-menopausal, whereas the rest 13% were postmenopausal. Out of 100 patients, 80% presented with a lump, and the rest, 20% presented with lump and ulceration, and 54% had this lump on the left side. 75% of patients manifested regional disease, whereas 25% of patients manifested local

show abstract

“…The idea of neoadjuvant chemotherapy has been recently applied to breast cancer treatment and studies have shown the efficacy of neoadjuvant chemotherapy in down-staging the primary tumor (1). The use of neoadjuvant chemotherapy thus allows breast conservation surgery to be performed instead of mastectomy.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Clinical and Pathological Response after Two Cycles of Neoadjuvant Chemotherapy on Sudanese Patients with Locally Advanced Breast Cancer

Alawad¹

2014

Ethiop J Health Sci

View full text Add to dashboard Cite

BackgroundThe use of neoadjuvant chemotherapy in treating breast cancer has shown efficacy in downstaging primary tumors, and allows breast conservative surgery to be performed instead of mastectomy. This study aims to evaluate patterns of clinical and pathological response after two cycles of neoadjuvant chemotherapy in patients with locally advanced breast cancer.Materials and MethodsThis is a prospective study. Ninety-eight patients who presented from April 2009 through May 2011 with locally advanced breast cancer and treated with neoadjuvant chemotherapy were included.ResultsThe clinical response rate was 83%; 11 patients (11.2%) had a complete clinical remission (cCR); 71 had a partial remission (72.4%); 13 had stable disease (13.3%), and 3 had progressive disease (3.1%). Seven patients had complete pathological response.ConclusionNeoadjuvant chemotherapy can achieve a high objective response rate in patients with locally advanced breast cancer even after two cycles. We recommend further research to find predictors for response.

show abstract

Feasibility of breast conservation after neoadjuvant taxene based chemotherapy in locally advanced breast cancer: a Prospective Phase I trial

Abstract: Background: Neoadjuvant chemotherapy is the standard care for locally advanced breast cancer. Our study aimed at evaluating the feasibility of breast conversation surgery (BCS) after neoadjuvant chemotherapy.

Cited by 7 publications

References 17 publications

A study on role of neo adjuvant chemotherapy in locally advanced non-metastatic breast cancer

A study on role of neo adjuvant chemotherapy in locally advanced non-metastatic breast cancer

Assessment of Clinico Pathological Factors as Predictive Markers in Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer (LABC)

Evaluation of Clinical and Pathological Response after Two Cycles of Neoadjuvant Chemotherapy on Sudanese Patients with Locally Advanced Breast Cancer

Contact Info

Product

Resources

About